Surviving the Tidal Wave

Disease is getting more complex, development costs are skyrocketing and payers are demanding value-based, real-world assessment to counter the rising cost of healthcare – the dilemma facing pharma is well known.Following the publication of a new report,Facing the Tidal Wave, a Partner at Deloitte, Hanno Ronte,  shares some of the emerging strategies that pharma can employ to manage risk and simultaneously pursue innovation in drug development.A tidal wave?The healthcare equivalent of global warming, the tidal wave Deloitte refers to is the growing complexity of disease. In the past decades, pharma has been very successful in developing highly effective medicines and vaccines that have increased life expectancy and improved quality of life for many patients.However, the associated costs of age-related illnesses such as cancer and dementia, as well as behavior-related conditions such as obesity and diabetes, have swelled. The prevalence of ‘metabolic syndrome’ across US and UK hospital patient populations might only be 5%, but it accounts for 35-40% of hospital costs.Meanwhile, our knowledge on illnesses – life-threatening, chronic, orphan – and their causes/pathways is broadening, while developments in genomics have expanded our understanding of individual genetic responses to therapies. Precision medicines with small-to-medium-sized patient populations are demanding attention from the healthca re system.Along with this tidal wave of diseases, pharma companies are b...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news